期刊文献+

CD4^+CD25^+Foxp3^+调节性T细胞在肿瘤免疫治疗中的研究进展

原文传递
导出
摘要 调节性T细胞(regulatory T cell,Treg)是一群发挥免疫抑制功能的淋巴细胞,在维持机体内环境稳定、预防自身免疫病、控制移植排斥中发挥重要作用,但却抑制了机体的抗肿瘤免疫。最近几年,有关Treg作为肿瘤的免疫治疗的靶细胞研究很多,本综述总结了这些研究的新进展,分析通过抑制Treg进行肿瘤免疫治疗的各种手段以及存在的隐患。
出处 《现代免疫学》 CAS CSCD 北大核心 2009年第6期522-525,共4页 Current Immunology
基金 上海市科委基础研究重点基金资助项目(07JC14045)
  • 相关文献

参考文献19

  • 1Curiel TJ. Regulatory T cells and treatment of cancer [J]. Curr Opin Immunol, 2008,20:241-246.
  • 2Curiel TJ. Tregs and rethinking cancer immunotherapy [J]. J Clin Invest, 2007,117:1167-1174.
  • 3Valzasina B, Piconese S, Guiducci C, et al. Tumor -induced expansion of regulatory T Cells by conversion of CD4^+ CD25^+ lymphocytes is thymus and proliferation independent [J]. Cancer Res, 2006,66:4488- 4495.
  • 4李卫鹏,王福庆.CD4^+CD25^+ Treg的免疫调节作用机制以及临床研究进展[J].现代免疫学,2006,26(2):164-167. 被引量:18
  • 5Kosmaczewska A, Ciszak L, Potoczek S, et al. The significance of Treg cells in defective tumor immunity [J]. Arch Immunol Ther Exp (Warsz), 2008,56:181-191.
  • 6Steitz J, Bruck J, Lenz J, et al. Depletion of CD25^+ CD4^+ T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8^+ T-cell-dependent immune defense of B16 melanoma [J]. Cancer Res, 2001,61:8643-8646.
  • 7Kohm AP, McMahon JS, Podojil JR, et al. Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4^+ CD25^+ T regulatory cells [J]. J Immunol, 2006,176 :3301-3305.
  • 8Powell DJ Jr, Attia P, Ghetie V, et al. Partial reduction of human Foxp3^+ CD4^+T cells in vivo after CD-25-direceted recombinant immunotoxin administration [J]. J Immunol, 2008,31:189-198.
  • 9Kreitman RJ, Pastan I. Immunotoxins in the treatment of hematologic malignancies [J]. Curr Drug Targets, 2006,7 : 1301-1311.
  • 10Nair S, Boczkowske D, Fassnacht M, et al. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity [J]. Cancer Res, 2007,67:371-380.

二级参考文献37

  • 1Dou J, Chu LL, Zhao FS, etal. Study of immunotherapy of murine myeloma by an IL-21-based tumor vaccine in Balb/ c mice[J]. Cancer Biol Ther, 2007, 6:1871-1879.
  • 2Kasaian MT, Whitters MJ, Carter LL. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity[J]. Immunity, 2002, 16:559-569.
  • 3Vollmer TL, Liu R, Price M, et al. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen[J]. Immunology, 2005, 174: 2696-2701.
  • 4Kowalczyk A, Wierzbicki A, Gil M, et al. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery[J]. Cancer Immunol Immunother, 2007, 56:1443-1458.
  • 5Thompson JA, Curti BD, Redman BG, et al. Interleukin-21 (IL-21): Tolerability and antitumor activity following two 5-day cycles in patients with stage Ⅳ melanoma (MM) or renal cell carcinoma (RCC)[J]. J Clin Oncd, 2006, 24: 101S.
  • 6Li YQ, Yee C. IL-21-mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8^+ cytotoxic T lymphocytes[J]. Blood, 2008,111: 229-235.
  • 7Parrish-Novak J, Dillon S R, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function[J]. Nature, 2000, 408: 57-63.
  • 8Davis ID, Skrumsager BK, Cebon J, et al. An open-label, two-arm, phase Ⅰ trial of recombinant human interleukin-21 in patients with metastatic melanoma[J]. Clin Caneer Res, 2007, 13:3630-3636.
  • 9Moroz A, Eppolito C, Li Q, et al. IL-21 enhances and sustains CD8^+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21 [J]. J Immunol, 2004, 173:900-909.
  • 10Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4^+ T lymphocytes[J]. J Immunol, 2007, 178: 732-739.

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部